Nuvectra Corporation12.13.16
Nuvectra Corporation, a neurostimulation medical device company, has announced the completion of a direct supply agreement with Minnetronix Inc..
Nuvectra was previously purchasing the peripheral devices that were manufactured by Minnetronix through Integer Inc. (formerly known as Greatbatch), which acted as a supplier intermediary between the two companies. The prior supply agreement was amended to establish a direct relationship between Nuvectra and Minnetronix. Nuvectra will begin purchasing the external peripheral devices for its Algovita spinal cord stimulation system directly from Minnetronix in the first half of 2017 as it transitions its supplier relationship from Integer.
“This new agreement is a next step in Nuvectra’s evolution as an independent company,” said Walter Berger, chief financial officer. “Part of that independence includes looking for ways to optimize our costs and supply chain. Our ability to directly manage the manufacturing and supply of the Algovita system’s external devices gives us greater control over not only our supply costs, but inventory control as well. We look forward to continuing to grow our positive working relationship with Minnetronix over the coming months.”
“Minnetronix has worked with the team at Nuvectra for many years on the development of the suite of peripheral devices for Algovita,” said Rich Nazarian, president and CEO of Minnetronix. “We are excited to continue our partnership with Nuvectra by establishing a direct manufacturing relationship, and look forward to supporting the team on the development of other neurostimulation systems going forward.”
Nuvectra is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita Spinal Cord Stimulation (SCS) System is its first commercial offering and is CE marked and U.S. Food and Drug Administration-approved for the treatment of chronic pain of the trunk and/or limbs. The technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, the NeuroNexus subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market.
St. Paul, Minn.-based Minnetronix develops electronic and electromechanical devices. The firm was founded in 1996.
Nuvectra was previously purchasing the peripheral devices that were manufactured by Minnetronix through Integer Inc. (formerly known as Greatbatch), which acted as a supplier intermediary between the two companies. The prior supply agreement was amended to establish a direct relationship between Nuvectra and Minnetronix. Nuvectra will begin purchasing the external peripheral devices for its Algovita spinal cord stimulation system directly from Minnetronix in the first half of 2017 as it transitions its supplier relationship from Integer.
“This new agreement is a next step in Nuvectra’s evolution as an independent company,” said Walter Berger, chief financial officer. “Part of that independence includes looking for ways to optimize our costs and supply chain. Our ability to directly manage the manufacturing and supply of the Algovita system’s external devices gives us greater control over not only our supply costs, but inventory control as well. We look forward to continuing to grow our positive working relationship with Minnetronix over the coming months.”
“Minnetronix has worked with the team at Nuvectra for many years on the development of the suite of peripheral devices for Algovita,” said Rich Nazarian, president and CEO of Minnetronix. “We are excited to continue our partnership with Nuvectra by establishing a direct manufacturing relationship, and look forward to supporting the team on the development of other neurostimulation systems going forward.”
Nuvectra is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita Spinal Cord Stimulation (SCS) System is its first commercial offering and is CE marked and U.S. Food and Drug Administration-approved for the treatment of chronic pain of the trunk and/or limbs. The technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, the NeuroNexus subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market.
St. Paul, Minn.-based Minnetronix develops electronic and electromechanical devices. The firm was founded in 1996.